Shots:
- Bracco Imaging & Subtle Medical have received the European MDR CE Mark approval for their AI-powered AiMIFY software for brain MRI; phased commercial availability expected from late 2025 to early 2026
- AiMIFY has depicted consistent efficacy across extensive validation data, incl. diverse pts demographics, pathologies, lesion sizes, MRI sequences, scanner vendors, & acquisition orientations
- AiMIFY uses advanced AI to amplify brain MRI contrast beyond the labelled GBCA doses, thereby improving visualization of small or poorly enhanced lesions for early detection & assessment
Ref: Prnewswire| Image: Bracco Imaging & Subtle Medical| Press Release
Related News:- Celltrion’s Yuflyma (Biosimilar, Humira) Receives the US FDA’s Interchangeability Designation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
